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Abstract
Background: Reducing immunosuppression can effectively treat BK viremia (BKV)
and BK nephropathy, but has been associated with increased risks for acute rejection and development of donor-specific antibodies (DSA). To date there have been
no systematic evaluations of re-escalating immunosuppression in transplant patients
with resolving BKV. Importantly, the safety of this approach and impact on graft
survival is unclear.
Methods: We performed a single-center retrospective review of kidney transplant
recipients between July 2011 and June 2013 who had immunosuppression reduction
after developing BKV (plasma PCR ≥ 1000 copies/ml). Changes in immunosuppression and patient outcomes were tracked until occurrence of a complication event:
biopsy-proven acute rejection (BPAR), detection of de novo DSA, or recurrent BKV.
Patients were grouped according to whether or not net immunosuppression was
eventually increased.
Results: Out of 88 patients with BKV, 44 (50%) had net immunosuppression increased while the other 44 did not. Duration of viremia, peak viremia, induction, and
sensitization status were similar between the two groups. In a Kaplan-Meier analysis, increasing immunosuppression was associated with less BPAR (P = .001) and a
trend toward less de novo DSA development (P = .06). Death-censored graft survival
(P = .27) was not different between the two groups. In the net immunosuppression
increase group, recurrent BKV occurred in 22.7% without any BKV-related graft
losses.
Conclusion: These findings support potential benefits of increasing immunosuppression in patients with low-level or resolved BKV, but prospective trials are needed to
better understand such an approach.
KEYWORDS

BK polyoma virus, graft survival, immunosuppressive regimens, infectious complication,
kidney transplant, rejection: T-cell–mediated (TCMR)

Abbreviations: AMR, antibody-mediated rejection; BKV, BK viremia; BKVN, BK virus nephropathy; BPAR, biopsy-proven acute rejection; CNI, calcineurin inhibitor; DSA, donor-specific
antibodies; IQR, interquartile range; ISx, immunosuppression; IVIG, intravenous immune globulin; MFI, mean fluorescence intensity; PCR, polymerase chain reaction; PRA, panel
reactive antibody; rATG, rabbit anti-thymocyte globulin; SD, standard deviation; TCMR, T-cell–mediated rejection.
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1 | I NTRO D U C TI O N

mL (>120 days), and all patients were discharged on mycophenolate mofetil 2000 mg/day or mycophenolate sodium 1440 mg/

BK polyomavirus resides latent in the renourinary epithelium and

day. Prednisone was decreased to 5-10 mg/d within 6 months of

can reactivate after kidney transplant to cause irreversible renal

transplant.

tubular damage and progressive graft dysfunction.1 BK viremia
(BKV) occurs in 10%-30% of kidney transplant recipients while
1%-10% of patients develop BK virus nephropathy (BKVN). 2,3 BK

2.2 | BKV screening and management

infection is considered a sequela of over-immunosuppression, and
given the lack of effective anti-viral therapies, reducing immuno-

Institution protocol required plasma BK PCR screening (Viracor™

suppression has emerged as the primary management strategy for

assay, Viracor Eurofins, Lee's Summit, MO) at 1, 3, 6, 9, 12, 18,

BKV.4,5

and 24 months, and patients underwent protocol biopsies at 3, 6,

Accumulating data suggest that BKV and BKVN are associated

and 12 months post-transplant. Additionally, a plasma BK PCR

with the development of de novo donor-specific antibodies (DSA) as

was ordered when an indication biopsy was performed for graft

well as acute rejection.

6–12

In biopsy series documenting the histo-

dysfunction.

logic evolution of definite and/or presumptive BKVN, approximately

Immunosuppression was generally modified in patients with a

40% of graft losses were compounded by rejection and Drachenberg

plasma BK PCR ≥ 1000 copies/mL and involved a stepwise approach

et al reported that rejection increased the risk of graft loss by four-

of holding or dose reducing mycophenolate by 50% followed by a

fold.

6,7

Rejection may be explained through cytokine release and

reduction in the tacrolimus target trough to 3-5 ng/mL. Tacrolimus

by T cells directed at BK virus thereby triggering an alloreactive im-

trough was adjusted if patients did not achieve a 50% reduction in

mune response.13,14 Another hypothesis is that reduced immunosup-

viral load or a plasma BK PCR value < 5000 copies/mL after 8 weeks

pression as part of BKV treatment elicits immune reactivation and

of reduced mycophenolate dosing. If biopsy-proven BKVN occurred,

subsequent rejection. Given the threat to graft survival after insults

mycophenolate was discontinued. Leflunomide and intravenous im-

from BKVN and successive rejection ensue, immunosuppression

mune globulin (IVIG) could be used at clinician discretion.

management in these patients needs to be critically evaluated.15,16
To the best of our knowledge, the impact of re-escalating immunosuppression in patients with resolving BKV has not been sys-

2.3 | Donor-specific antibody screening

tematically studied. Furthermore, the safety of this approach and
the effects on rejection and graft survival have not been explored.

Donor-specific antibody screening was performed at 12 months and

At our institution, a variety of approaches existed amongst trans-

yearly thereafter for 5 years total as well as at the time of indication

plant nephrologists’ immunosuppressive medication adjustments in

biopsy using the Luminex® single antigen bead assay (One Lambda,

patients with improving BKV, enabling a retrospective comparison

Inc, West Hills, CA). Patients at high immunological risk (positive

between different management approaches. In this study, patients’

crossmatch, preformed DSA, history of antibody-mediated rejection

immunosuppressive medications were initially decreased to treat

[AMR] or desensitization) or intermediate immunological risk (peak

BKV. We then compared outcomes between patients who subse-

PRA > 20%, re-transplant, African American, T-cell–mediated rejec-

quently had a net increase in their immunosuppression regimen and

tion [TCMR] ≥Banff 2A) underwent additional DSA screening either

patients whose immunosuppression was not increased.

monthly for the first 6 months or at months 3 and 6, per the high and
intermediate immunological risk protocols, respectively.

2 | M ATE R I A L S A N D M E TH O DS
2.1 | Immunosuppression

2.4 | Study design
This single-center study was completed by retrospective chart re-

Protocol induction therapy included rabbit anti-thymocyte globulin

view of kidney and combined-kidney transplant recipients trans-

(rATG) 5 mg/kg cumulative dose for high-immunologic risk patients

planted between July 2011 and June 2013. Patients with less than

(panel reactive antibody [PRA] >20%, African-American, living-

one year of BK PCR screening from transplant were excluded. The

unrelated donor transplant, ABO incompatible transplant, positive

index event for study inclusion was defined as post-transplant BKV

crossmatch, delayed graft function, presence of DSA, or history

with a peak PCR of ≥1000 copies/mL which was generally man-

of de-sensitization therapy) while all other patients received no

aged initially by net immunosuppression reduction. Each immuno-

induction. Basiliximab could be substituted for rATG in individuals

suppression dose adjustment after the index event was tracked to

deemed to be at excessive infectious risk. Triple-drug therapy with

determine if immunosuppression doses were eventually re-esca-

tacrolimus, mycophenolate mofetil, and prednisone were used for

lated and patients were divided into two groups: net immunosup-

maintenance immunosuppression. Tacrolimus trough targets were

pression increase or no net immunosuppression increase. Patients

8-12 ng/mL (0-90 days), 6-10 ng/mL (91-120 days), and 4-8 ng/

were included in the net immunosuppression increase group if their

|
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mycophenolate dose was increased and/or the tacrolimus target

in 36 patients after the viral load increased in 24 (66.7%) patients or

trough was increased compared to the initial reduction made at the

due to insufficient viral load decline in 12 (33.3%) patients. Of these

time of the index event.

12 patients, 11 (91.7%) patients had immunosuppression reduced

All charts were screened for two complications indicative of un-

again after the plasma BK PCR decreased by less than 0.5 log10 cop-

der-immunosuppression, including biopsy-proven acute rejection

ies/mL after a median of 46 days (IQR: 27-82.3 days) from when im-

(BPAR: TCMR ≥Banff 1A or AMR) and de novo DSA with ≥700 mean

munosuppression was first reduced.

fluorescence intensity (MFI). Biopsies were read according to the

There were 44 patients who had an eventual net increase in im-

2007 Banff scoring.17 In the group of patients whose net immuno-

munosuppression after the index BKV event. Immunosuppression

suppression was eventually increased after BKV improved, charts

was increased in 18 (40.9%) patients after the virus was no longer

were also screened for recurrent BKV, a complication suggestive of

detected by plasma PCR, and in 26 (59.1%) patients who had low-

over-immunosuppression. Study definition of recurrent BKV was

level viremia, with a median viral burden of 1000 copies/mL (IQR:

met if a net increase in immunosuppression was followed by a rising

300-1725 copies/mL). Patient characteristics were well matched

viral load that prompted the clinician to subsequently decrease the

between patients with and without a net increase in immunosup-

level of immunosuppression.

pression (Table 1). Importantly, the median of the peak viral load

Study follow-up ended when the first of any three complication

in the group with no increase in net immunosuppression was 7200

events occurred, treating them as competing endpoints: BPAR, de

copies/mL (IQR: 2375-38 350 copies/mL) and was comparable to

novo DSA, or recurrent BKV. Immunosuppressant dosing at least

10 200 copies/mL (IQR: 4400-50 025 copies/mL) in the group with

4 weeks prior to one of these complications, or at the date of last

an increase in net immunosuppression (P = .23). Likewise, near-equal

lab if no complication occurred, was used to classify patients into

proportions of patients in the no net increase (45.5%) or net increase

either the net immunosuppression increase group or no net immu-

(50.0%) groups had a peak PCR ≥ 10 000 copies/mL (P = .67). The

nosuppression increase group. The two groups were compared for

median time from transplant to BKV onset was similar (P = .47),

all-cause graft failure and composite complication comprised of

160.5 days (IQR: 55.8-240.5 days) in the group without a net in-

BPAR and de novo DSA. Recurrent BKV was reviewed separately

crease and 101.5 days (IQR: 58.3-198.8 days) in the group with a net

to evaluate safety of increasing net immunosuppression in patients

increase in immunosuppression.

with improving BKV.

Patients had a median follow-up of 3.4 years (IQR: 1.1-5.0 years),
which concluded when they had the first complication event (BPAR,

2.5 | Statistical analysis

de novo DSA or recurrent BKV) or at last lab follow-up if no complications occurred. Patients in the net increase group were more
likely to achieve initial BK viral clearance (77.3% vs 52.3%, P = .01).

For statistical comparison of the demographic data, the chi-square

However, the median times from index event to BK clearance were

or Fisher's exact test were used for categorical variables while the

similar between the net increase group and the no net increase

Student's T test or Mann-Whitney U tests were used for continuous

group (176 days [IQR: 99-376 days] vs 126 days [IQR: 72-175 days],

variables as appropriate. Mean ± standard deviation (SD) was calcu-

respectively; P = .10). Numerically more patients in the no net in-

lated for normally distributed continuous data. For non-normally dis-

crease group experienced a complication event (63.6% vs 50%,

tributed data, median and interquartile range (IQR) were reported.

P = .20), which resulted in a shorter time from index event to compli-

Kaplan-Meier survival analyses with log-rank test were conducted

cation event of 1.2 years (IQR: 0.4-3.6 years) in the no net increase

to compare the two groups for time to BPAR, de novo DSA and com-

group compared to 3.5 years (IQR: 1.1-5.0 years) in the net increase

posite complication events.

group (P = .001). One patient in each group received leflunomide,
and there was no significant difference in frequency of IVIG admin-

3 | R E S U LT S

istration between the net immunosuppression increase (11 of 44
patients, 25%) and no net increase (5 of 44 patients, 11.4%) groups
(P = .10). Mean estimated glomerular filtration at 12 and 24 months

Out of 422 kidney transplant recipients that were screened, 88

after transplant were not significantly different between the groups.

had BKV with a peak PCR ≥ 1000 copies/mL. Patients were mostly
Caucasian (62.5%), male (68.1%), received a deceased donor transplant (54.5%), and rATG (71.6%) for induction. The median viral load

3.1 | Graft survival

that prompted initial reduction in immunosuppression was 7200
copies/mL (IQR: 2300-33 000 copies/mL) in the no net immuno-

Overall graft survival was better when net immunosuppression was

suppression increase group and 7100 copies/mL (IQR: 3400-14 350

increased although there was no difference in death-censored graft

copies/mL) in the net increase group (P = .58). BKV was managed by

failure between the groups (Figure 1A,B). Of the seven patients with

either reduction or discontinuation of mycophenolate in 86 (97.7%)

death-censored graft failure in the group without a net increase

patients and 15 patients in each group had target tacrolimus troughs

in immunosuppression, 5 (71.4%) graft losses were attributed to

decreased. Net immunosuppression was reduced for a second time

chronic rejection, and one graft loss was related to acute AMR and

4 of 9

|

TA B L E 1

COTIGUALA et al.

Demographics and baseline characteristics
Net ISx not increased (n = 44)

Net ISx increased (n = 44)

P-value

Mean age, year (SD)

52 (15.7)

51 (14.6)

.65

Male, n (%)

30 (68.1)

30 (68.1)

1

27 (61.4)

28 (63.6)

.85

Race, n (%)
Caucasian
Black

12 (27.2)

9 (20.5)

Asian

1 (2.3)

2 (4.5)

Other

4 (9.1)

5 (11.4)

Cause of ESRD, n (%)
Hypertension

6 (13.6)

7 (15.9)

Diabetes mellitus

13 (29.6)

18 (40.9)

Polycystic kidney disease

3 (6.8)

6 (13.6)

Glomerulonephritis

6 (13.6)

3 (6.8)

FSGS

2 (4.6)

1 (2.3)

Other

14 (31.8)

9 (20.5)

.57

Re-transplant, n (%)

3 (6.8)

2 (4.5)

1

Simultaneous pancreas-kidney
transplant, n (%)

2 (4.5)

2 (4.5)

1

Heart-kidney transplant, n (%)

1 (2.3)

0

1

Liver-kidney transplant, n (%)

1 (2.3)

0

1

Class I peak

17.6 (27.3)

17.0 (30.8)

.93

Class II peak

19.5 (32.0)

10.0 (23.5)

.12
.5

Mean PRA, % (SD)

Donor characteristics, n (%)
Deceased

23 (52.3)

25 (56.8)

Living related

9 (20.4)

5 (11.4)

Living unrelated

12 (27.3)

14 (31.8)

Induction, n (%)
rATG

30 (68.2)

33 (75.0)

Basiliximab

2 (4.5)

1 (2.3)

None
Leflunomide use, n (%)

12 (27.3)

10 (22.7)

1 (2.3)

1 (2.3)

.72

1

IVIG use, n (%)

5 (11.4)

11 (25.0%)

.1

Delayed graft function, n (%)

5 (11.4)

7 (15.9)

.76

1.5 (0.6)

1.4 (0.4)

.37

Mean creatinine, mg/dL (SD)
3 month
6 month

1.4 (0.5)

1.4 (0.8)

.93

12 month

1.5 (0.5)

1.3 (0.4)

.07

24 month

1.5 (0.7)

1.4 (0.5)

.29

Mean eGFR a , ml/min per 1.73 m2 (SD)
12 month

53.3 (16.4)

59 (16.2)

.11

24 month

53.7 (18.6)

56.8 (18.5)

.45

Abbreviations: ESRD, end stage renal disease; FSGS, focal segmental glomerulosclerosis; ISx, immunosuppression; IVIG, intravenous immune
globulin; PRA, panel reactive antibody; rATG, rabbit anti-thymocyte globulin; SD, standard deviation.
a

Calculated by Modification of Diet in Renal Disease (MDRD) equation.

BKVN each. In the group with a net increase in immunosuppres-

rejection and one graft loss was related to cardiorenal disease.

sion, 2 of 3 (66.7%) death-censored graft failures were from chronic

Cardiovascular events were the most common cause of death: two

|
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Proportion of Functioning Grafts

(A)

increase group. Overall, there were 19 (21.6%) patients in the entire

100%

cohort with BPAR that occurred after the development of BKV, of

75%

majority (89.5%) of BPAR episodes after BKV were T-cell–mediated

which 14 (73.7%) patients were in the no net increase group. The
rejections.
P=0.04

50%

The SV40 staining was negative in 16/19 (84.2%) patients and
not tested in 2/19 (10.5%) patients diagnosed with BPAR. Although
one patient with BPAR (Banff 1B) also had scattered weak nuclear

25%

SV40 positivity of unclear significance on biopsy, the diagnosis of
rejection was strengthened by the diffuse inflammation and tu-

0%
0

Number at risk
group = 0 44
group
44

1

2

41
36

42
39

3

4

5

6

7

11
19

2
4

42
40

41
40

32
33

bulitis in many areas away from the positive signal. Of all patients
with BPAR after BKV, only the two patients diagnosed with AMR

analysis time (years)

No Net ISx increase

had positive C4d staining. As assessed by survival estimates, significantly more patients without a net increase in immunosuppression
developed BPAR (P = .001), with each of these episodes except for

Net ISx increase

one occurring within one year of BKV (Figure 2A).

(B)
Proportion of Functioning Grafts

5 of 9

Between the index BKV event and the first complication event

100%

(or last lab follow-up if no complication event occurred), an average

75%

of 3.5 ± 2.3 DSA tests per patient were checked in the no net in-

P=0.27

crease group and an average of 5.1 ± 4.4 DSA tests per patient were
ordered in the net increase group (P = .04). More DSA screenings

50%

were likely ordered in the net increase group as these patients were
less likely to develop de novo DSA and BPAR, and were therefore

25%

followed for longer according to study design. Although risk of developing de novo DSA was not statistically different between the

0%
0

Number at risk
group = 0 44
group = 1 44

1

2
3
4
5
analysis time (years)

6

7

41
36

42
39

11
19

2
4

42
40

No Net ISx increase

41
40

32
33

two groups (P = .06), de novo DSA formation was numerically higher
in patients without a net increase in immunosuppression, 34.1% vs

Net ISx increase

F I G U R E 1 Graft Survival. (A) Overall graft survival (noncensored for death; P = .04) but not (B) death-censored graft
survival (P = .27) was worse when the net immunosuppression was
not increased

15.9% (Figure 2B). Adjustment in net immunosuppression was associated with a significant difference in the composite complication
events of BPAR and de novo DSA (P = .0004, Figure 2C). Median
time to de novo DSA after BKV was 335 days (IQR: 96.5-718 days)
in patients with no net immunosuppression increase. Of the 21 patients with de novo DSA, 19% had class I DSA, 61.9% had class II
DSA, and 19% had both class I and II DSA. The median MFI of the
immunodominant de novo DSA was higher for class II compared to
class I DSA (1,978 MFI [IQR: 1,015-2,105 MFI] vs 5,134 MFI [IQR:

patients in the net increase group, one of whom was a heart-kidney

2,853-11,006 MFI], P = .01). Of the six patients with a combined

transplant recipient, and one patient in the group without a net in-

kidney transplant, none developed de novo DSA in either group and

crease. An additional three patients whose net immunosuppression

one simultaneous pancreas-kidney transplant recipient in the no net

was not increased died, one from infection and two deaths from un-

increase group experienced TCMR.

known causes.

3.2 | Biopsy-proven acute rejection and
de novo DSA

3.3 | Recurrent BK viremia after
immunosuppression re-escalation
An average of 3.1 ± 2.0 quantitative BKV PCRs per patient were

Biopsy-proven acute rejection episodes before the onset of index

ordered within the first three months after increasing net immuno-

BKV as well as rejection episodes that occurred after index BKV up

suppression, and an average of 27.2 ± 21.0 quantitative BK PCRs

to the first complication event/last lab follow-up (if no complication

per patient were ordered between the time of increasing net im-

event occurred) are recorded in Table 2. Rates of BPAR before index

munosuppression to last lab follow-up. After the net immunosup-

BKV were not significantly different between groups (P = .33). Of

pression was increased, 10 (22.7%) patients experienced recurrent

the 19 patients who developed BPAR after BKV, only one had a pre-

BKV that prompted the clinician to subsequently decrease main-

vious BPAR (Banff 1A) episode, and this patient was in the no net

tenance immunosuppression. In patients with recurrent BKV, the

6 of 9
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Net ISx, not increased
(n = 44)

TA B L E 2 Biopsy-proven acute
rejection characteristics

Net ISx Increased (n = 44)

Rejection events before the index event of BKV
Any rejection, n (%)

7 (15.9%)

4 (9.1%)

T-cell–mediated rejection,
n (%)

7 (15.9%)

4 (9.1%)

Banff 1A a

4 (57.1%)

0

a

2 (28.6%)

2 (50%)

Banff 2A a

1 (14.3%)

1 (25%)

Banff 1B

a

.33

0

1 (25%)

Antibody-mediated
rejection, n (%)

0

1 (25%)

Median days from BPAR to
index BKV, days (IQR)

100 (55.5-374.5)

114 (42.5-255)

.53

.02

Banff 2B

Rejection events after the index event of BKVb
Any rejection, n (%)

14 (31.8%)

5 (11.4%)

T-cell–mediated rejection,
n (%)

12 (27.3%)

5 (11.4%)

Banff 1A a

4 (33.3%)

3 (60.0%)

Banff 1Ba

4 (33.3%)

2 (40.0%)

Banff 2A a

a

4 (33.3%)

0

Antibody-mediated
rejection, n (%)

2 (4.5%)

0

Median days from index
BKV to BPAR, days (IQR)

146 (79.8-156)

203 (188-437)

.003

Out of composite cases.

b

Includes rejection events occurring after index BKV up to the first complication event (ie BPAR,
de-novo DSA, recurrent BKV) or last lab follow-up if no complication event occurred.

clinician elected to decrease immunosuppression after quantitative

administered early after transplant. This was a proof-of-concept

viral load doubled compared to the PCR value when immunosup-

study evaluating the overall impact of increasing net immunosup-

pression was first increased (6 of 10 patients, 60%) or after the viral

pression in patients with resolving BKV. The major finding was that

load rose to ≥1000 copies/mL after previously being undetected (2

this approach appeared to improve rejection-free survival and nu-

of 10 patients, 20%). In the other two (20%) patients, immunosup-

merically fewer patients developed de novo DSA compared to the

pression was decreased after less than a twofold rise in the quan-

control group whose net immunosuppression was not increased.

titative viral load, but reached 2100 copies/mL in one patient and

The 21.6% incidence of BKV observed was consistent with other

12 300 copies/mL in the other case. There were no graft losses

reports where similar immunosuppression protocols were used.8,12

due to BKVN in patients with recurrent BKV at the time of last lab

In addition, the rates of BPAR and de novo DSA were within the

follow-up.

ranges referenced in the literature, 12%-50% and 3.3%-79%, respectively.8–12,16 The incidence of antibody-medication rejection

4 | D I S CU S S I O N

may have been underestimated by our study since the 2007 Banff
schema were applied, and current classification no longer requires
positive C4d staining or detection of DSA.18

Based on the philosophy that BKV occurs due to excessive immuno-

The two groups were remarkably well matched for the degree

suppression, providers at our center traditionally maintained a mini-

of patient sensitization, median peak BK viral load, proportion of

mized immunosuppression regimen after BKV improved or resolved.

patients with a peak PCR ≥ 10 000 copies/mL, median time to BK

However, the increasing reports of late rejection or de novo DSA

viral clearance and the rATG induction use. Despite being a retro-

development after BKV prompted some nephrologists to attempt

spective evaluation, the comparable distribution of immunologic

an increase in net immunosuppression, and recurrent BKV was

and viral characteristics between the two groups suggest nephrol-

often not observed. As a result, a competing philosophy emerged

ogists had similar information at the time net immunosuppression

that it may be possible to increase immunosuppression especially

was evaluated; thus, a natural experiment comparing immuno-

as patients are farther away from the intensive immunosuppression

suppression adjustments in patients with BKV was possible. The
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BPAR-Free Graft Survival

(A)
100%

provided rich data from the usual patient care and enabled studying BKV and complications.
Our findings could be impactful as patients developing acute

75%

rejection and de novo DSA are more likely to experience prema-

P=0.001

ture graft loss, especially when rejection occurs after BKV.15,16,19,20

50%

Although a statistical difference in death-censored graft failure was
not observed in our study (in part due to low event rates in both

25%

groups during follow-up period), graft losses due to acute or chronic
rejection occurred in three-times the number of patients whose net
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De novo DSA-Free Graft Survival

immunosuppression was not increased. Increasing immunosuppression after BKV improved was associated with recurrent BKV in less
than 25% of patients, and none of these patients experienced graft
loss related to BKVN at the end of last lab follow-up. These results
suggest that in patients with resolving BKV, net immunosuppression

Net ISx increase

may be safely increased in some patients.

(B)

Outcomes of immunosuppression reduction strategies during

100%

BKV treatment have been extensively studied.8,10,21–24 In patients
with BKV, tacrolimus reduction by ≥20% within 1 month of BKV di-

75%

P=0.06

agnosis was recently associated with acute rejection rates of 34.2%
compared to 7.9% in patients with less aggressive modifications

50%

(P = .008).16 Meanwhile, gradual immunosuppression tapering has
been protective against DSA development when dosing modifica-

25%

tions were made at slower 4-week intervals compared to 2-week
intervals.10 Bischof et al demonstrated BKV clearance in 96% of

0%
0
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patients and low rates of TCMR (7%) and AMR (4%) when the calcineurin inhibitor (CNI) was reduced first, and secondarily the anti-metabolite dose was decreased if BKV did not improve; investigators
hypothesized decreasing the CNI first may allow for a stronger T-cell
response towards BK virus, while continuing mycophenolate may

Net ISx increase

be protective against AMR since B-cell proliferation remains inhib-

(C)
100%

ited. 24 These findings aid the clinician in minimizing immunosuppression. In contrast, studies comparing approaches to re-escalating net

75%

immunosuppression after BKV resolution are not available.
Various practices have been reported regarding adjusting net
immunosuppression after BKV. For example, Hardinger et al de-

50%

P=0.0004
P=0.0004

25%

scribed that 10 of 11 (91%) patients with sustained BKV (>1 month)
did not have an antimetabolite restarted 5 years after transplant

0%

BPAR and DSA Free Graft Survival
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post-transplant. 21 It should be noted that 5-year rejection rates

despite 95% of patients achieving BKV resolution within 1 year
0
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F I G U R E 2 Individual and Composite Complications: BPAR
and de novo DSA. Increasing net immunosuppression was
associated with less (A) BPAR (P = .001), but had no significant
effect on (B) de novo DSA development (P = .06). Escalating net
immunosuppression had protective effect on (C) composite BPAR
and de novo DSA development (P = .0004)

were not different in patients with or without BKV (11% vs 22%,
P = .164) despite not routinely increasing net immunosuppres-

sion. 21 However, this study did not employ surveillance DSA testing or protocol biopsies, which is a strength of our study. In more
recent studies, increasing net immunosuppression appears to have
been practiced by some clinicians. For example, the institution
protocol in the Sawinski et al study allowed for re-introduction
of the anti-metabolite after BKV clearance according to clinician
judgment.12 In the Elfadawy et al study, only patients with persistent high BKV (peak viral ≥ 10 000 copies/mL and BKV duration of >3 months), but not patients with low or transient BKV,

protocol-driven post-transplant management of BK PCR screen-

were maintained on a regimen with significantly reduced mean

ing, surveillance biopsies, DSA monitoring, and use of the same

mycophenolate or tacrolimus levels after BKV compared to lev-

Viracor assay in all patients for the duration of the study period

els from aviremic controls. 8 Although these studies suggest net
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immunosuppression may have been increased in some patients,

collection, data analysis/interpretation, drafting article, critical revi-

it is not possible to determine whether escalation of the CNI or

sion of article.

mycophenolate dosing should be prioritized in patients with improving BKV.
Given the retrospective nature of this study, the data was not
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5 | CO N C LU S I O N
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needed to determine if these results can be replicated in a larger
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